

Preliminary Programme



isirv
International Society for
Influenza and other
Respiratory Virus Diseases

Correlates of Protection for Next Generation Influenza Vaccines: Lessons Learned from the COVID Pandemic

1 - 3 March 2023 Seattle | USA

Day 1 Wednesday 1 March

08:00 Registration / Poster Mounting

09:00 **Welcome and Opening Remarks** **Ros Hollingsworth** Bill & Melinda Gates Foundation, USA

Session A **Lessons Learned from the COVID Pandemic and New COVID Vaccine Platforms**
Chairs: Jackie Katz The Taskforce for Global Health Inc., USA **Joe Bresee** The Taskforce for Global Health Inc., USA

09:05 **Lessons Learned from New COVID Vaccines**
Sarah Gilbert University of Oxford, UK

09:35 **Lessons Learned from the COVID Pandemic**
Florian Krammer Icahn School of Medicine at Mount Sinai, USA

09:55 **What Can We Learn from the Human Challenge of SARS-CoV-2 and Flu?**
Chris Chiu Imperial College London, UK

10:20 **Correlates of Protection**
Miles Davenport Kirby Institute, UNSW Sydney, Australia

10:40	BREAK
Session B	<p>Next Generation/Universal Influenza Vaccine Chairs: Othmar Engelhardt NIBSC, UK Kanta Subbarao WHO Collaborating Centre, University of Melbourne, Australia</p>
11:10	<p>Universal Influenza Vaccine Florian Krammer Icahn School of Medicine at Mount Sinai, USA</p>
11:40	<p>Next Generation Influenza Vaccines Aaron Schmidt Harvard Medical School; Ragon Institute of MGH, MIT and Harvard, USA</p>
12:00	<p>Correlates of Protection from Cohort Studies to Guide Next Generation Influenza Vaccine Aubree Gordon University of Michigan, USA</p>
12:20	<p>Correlates of Protection for Next Generation/Universal Influenza Vaccine Arnold Monto University of Michigan, USA</p>
12:40	LUNCH
Session C	<p>Immunology B and T Cell Update Chairs: Florian Krammer Icahn School of Medicine at Mount Sinai, USA Diane Post NIH, USA</p>
14:00	<p>Role of T Cells in Vaccine Responses Shane Crotty La Jolla Institute for Immunology, CA, USA</p>
14:30	<p>B Cells After Influenza Vaccination Ali Ellebedy Washington University School of Medicine, St Louis, USA</p>
15:00	<p>CD8 T Cells in Protection from Influenza Paul Thomas St. Jude Children's Research Hospital, USA</p>
15:30	<p>Role of Non HI Antibodies in Protection from Influenza Galit Alter Massachusetts General Hospital, Boston, MA, USA</p>

16:00	BREAK
Session D	Mucosal Correlates of Immunity and Protection Chairs: Ali Ellebedy Washington University School of Medicine, St Louis, USA Ros Hollingsworth Bill & Melinda Gates Foundation, USA
16:30	Mucosal Correlates of Immunity and Protection Peter Openshaw Imperial College London, UK
17:00	Mucosal Data from LAIV Kanta Subbarao WHO Collaborating Centre, University of Melbourne, Australia
17:30	The Role of Mucosal Immunity to Influenza Stacey Schultz-Cherry St Jude Children’s Research Hospital, USA
17:50	Local Immunity After Influenza Vaccination Rebecca Cox , University of Bergen, Norway
18:10	The Role of Local Antibodies in SARS CoV-2 Protection Jennifer Gommerman University of Toronto, Canada
18:10	EVENING RECEPTION and POSTER SESSION

Day 2 Thursday 2 March

Session E

Immunological Assays

Chairs: **Rebecca Cox** University of Bergen, Norway **Paul Thomas** St Jude Children's Research Hospital, USA

09:00

Lessons Learned from the HIV Network

Adrian McDermot

09:30

Lessons Learned from SARS CoV-2 Assays

David Montefiori (remote)

Lessons Learned from FLUCOP

09:45

HA Assays **Othmar Engelhardt** National Institute for Biological Standards and Control, UK

10:05

NA Assays **Emanuele Montomoli** University of Siena, Italy

10:20

T Cell Assays **Gwenn Waerlop** Ghent University, Belgium

10:40

BREAK

Session F

Regulatory Session (hybrid)

Chairs: **Jerry Weir** FDA, USA **Chris Roberts** NIH, USA

11:10

Regulatory Hurdles for Next Generation Influenza Vaccines

David Vaughn Bill & Melinda Gates Foundation

11:40

PANEL DISCUSSION

How Can COP Help the Regulatory Process for Licensure of New Vaccines

Sarah Gilbert University of Oxford, UK

Chris Chiu Imperial College London, UK

Jerry Weir FDA, USA

Marco Caveleri EMA, The Netherlands

12:30	LUNCH
Session G	Epidemiology, Statistics and Data Science Chairs: Barbara Rath <small>ViVI</small> Sheena Sullivan <small>WHO Collaborating Centre for Reference and Research on Influenza, Peter Docherty Institute, Australia</small>
13:45	Influenza Vaccine Effectiveness Sheena Sullivan <small>WHO Collaborating Centre for Reference and Research on Influenza, Peter Docherty Institute, Australia</small>
14:15	Novel Study Design to Support Correlates of Protection Studies Peter B. Gilbert <small>University of Washington, USA</small>
14:45	Mathematical Modelling of Correlates of Protection Miles Davenport <small>Kirby Institute, UNSW Sydney, Australia</small>
15:05	PANEL DISCUSSION – Study Design for Correlates of Protection Aubree Gordon <small>University of Michigan, USA</small> Miles Davenport <small>Kirby Institute, UNSW Sydney, Australia</small> Sheena Sullivan <small>WHO Collaborating Centre for Reference and Research on Influenza, Peter Docherty Institute, Australia</small> Peter B. Gilbert <small>University of Washington, USA</small>
16:00	BREAK
Session H	Oral Abstracts Chairs: Mark Tompkins <small>University of Georgia, USA</small> Emanuele Montomoli <small>University of Siena, Italy</small>
16:30 -18:00	
19:30	SOCIAL EVENING

DAY 3 Friday 3 March

Session I

09:00 – 11:00

Oral Abstracts

Chairs: **Chris Chiu** Imperial College London, UK **Stacey Schultz-Cherry** St Jude Children's Research Hospital, USA

11:00

BREAK

Session J

11:30

Recap of Sessions A-C

Group Discussion –

Lessons Learned from COVID for Identifying Correlates of Protection and Develop Consensus on Immune Responses to Target

Florian Krammer Icahn School of Medicine at Mount Sinai, USA

Ali Ellebedy Washington University School of Medicine, St Louis, USA

Sarah Gilbert University of Oxford, UK

Kanta Subbarao WHO Collaborating Centre, University of Melbourne, Australia

12:30

LUNCH

Session K

13:45

Recap of Sessions D-F Group Discussion

The Way Forward in Correlates of Protection and Their Detection for Next Generation Vaccines. What are Relevant Immune Responses? | Best Assays Available | Approaches to Standardisation and Harmonisation

Othmar Engelhardt National Institute for Biological Standards and Control, UK

Jerry Weir FDA, USA

Rebecca Cox University of Bergen, Norway

Jackie Katz The Taskforce for Global Health Inc., USA

15:30	VISIT DISCOVERY CENTRE
16:30	Closing Remarks – End of Meeting Ros Hollingsworth Bill & Melinda Gates Foundation